GSK Plc’s (GSK) Biologics License Application for the use of Depemokimab in two indications are under review by the FDA, with a decision due on December 16, 2025.The proposed indications are as add-on maintenance treatment of asthma in adult and pediatric patients aged 12 years and older with type 2 inflammation characterised by an eosinophilic phenotype on medium- to high-dose inhaled corticosteroids (ICS) plus another asthma controller and, as add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).Depemokimab is a monoclonal antibody that targets IL-5, a key cytokine (protein) in type 2 inflammation. This type of inflammation is common in people with hard-to-control asthma and can cause flare-ups and hospital stays. It also affects up to 85% of people with chronic sinusitis with nasal polyps (CRSwNP) and is associated with more severe disease and symptoms.If approved, Depemokimab’s global sales are expected to reach $1.65 billion by 2031, according to GlobalData’s consensus forecast.GSK closed Wednesday’s (November 26, 2025) trading at $48.02, up 0.99%.